R.P. Boggs & Co. Regeneron Pharmaceuticals, Inc. Transaction History
R.P. Boggs & Co.
- $140 Million
- Q1 2025
A detailed history of R.P. Boggs & Co. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, R.P. Boggs & Co. holds 9,670 shares of REGN stock, worth $5.06 Million. This represents 4.37% of its overall portfolio holdings.
Number of Shares
9,670
Previous 9,279
4.21%
Holding current value
$5.06 Million
Previous $6.61 Million
7.2%
% of portfolio
4.37%
Previous 4.41%
Shares
17 transactions
Others Institutions Holding REGN
# of Institutions
1,471Shares Held
85.8MCall Options Held
1.39MPut Options Held
1.45M-
Vanguard Group Inc Valley Forge, PA9.41MShares$4.93 Billion0.11% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$4.42 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY5.66MShares$2.96 Billion0.28% of portfolio
-
State Street Corp Boston, MA4.79MShares$2.51 Billion0.13% of portfolio
-
Capital International Investors Los Angeles, CA3.99MShares$2.09 Billion0.52% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $56.1B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...